Published
April 6, 2026
If you bought generic Vivimed losartan, this $1.899 million settlement refunds what you paid for the NMBA-contaminated blood pressure pills — check your NDC number to confirm you are covered.
What Is This Settlement About?
Vivimed Life Sciences Pvt Ltd and Strides Pharma Science Limited (collectively, "Vivimed") have agreed to a $1,899,000 class action settlement to resolve economic loss claims that the company manufactured, distributed, and sold losartan blood pressure drugs contaminated with NMBA — a probable human carcinogen. The settlement is part of a massive multidistrict litigation in the U.S. District Court for the District of New Jersey covering contamination in generic valsartan, losartan, and irbesartan blood pressure medications. It is one of three related settlements — the largest being the $11.37 million Hetero Valsartan settlement for pills contaminated with NDMA. In a separate case, Strides also faces a testosterone gel benzene class action settlement over economic-loss claims tied to a different product.The lawsuit alleges that Vivimed violated state laws by manufacturing and selling losartan finished drug formulations that contained NMBA (N-nitroso-N-methyl-4-aminobutyric acid), a nitrosamine impurity classified as a probable human carcinogen. The contamination was allegedly introduced during the manufacturing of the active pharmaceutical ingredient (API). The settlement also covers losartan repackaged by Heritage Pharmaceuticals Inc. (doing business as Avet Pharmaceuticals Inc.).
Vivimed denies all allegations of wrongdoing and denies that the NMBA levels in its losartan were harmful or carcinogenic. The company agreed to settle to avoid the cost and uncertainty of continued litigation. This settlement resolves only the economic loss claims — meaning what consumers and insurers overpaid for a drug that was allegedly defective. It does not cover personal injury or medical monitoring claims, which are being litigated separately in the same MDL.
Status
Claims Open
final approval hearing scheduled June 30, 2026
Claim Deadline
June 2, 2026
Settlement Fund
$1,899,000
economic loss only · pro rata refund of purchase price
Proof Required
No
documentation encouraged but not strictly required · covers 8 impacted Vivimed losartan NDCs
Who Qualifies? Check Your NDC Number
You qualify if you are an individual in the United States who paid any amount of money for retail purchases of Vivimed losartan sold under one of these specific impacted National Drug Codes (NDCs):• 23155-644-09
• 23155-644-10
• 23155-645-03
• 23155-645-09
• 23155-645-10
• 23155-646-03
• 23155-646-09
• 23155-646-10
The NDC number is printed on your pill bottle label and on your pharmacy receipt. If you still have an old bottle of losartan, check the label. If not, your pharmacy can look up your prescription history and tell you which manufacturer and NDC you received. Most major pharmacies (CVS, Walgreens, Rite Aid, Walmart, Kroger, Costco, independent pharmacies) can print your prescription history for free upon request.
The settlement covers both individual consumers and third-party payors (like health insurers and welfare funds). Excluded from the class are Vivimed itself, pharmacy benefit managers, and most federal and state government entities.
How Much Can I Get?
The total settlement fund is $1,899,000. Attorneys' fees (up to one-third, or ~$633,000), litigation costs, settlement administration expenses, and service awards to the named plaintiffs will be deducted before distribution. The net fund will then be allocated between consumers and third-party payors according to a plan approved by the court.Individual payouts depend on how much you paid for Vivimed losartan during the class period and how many valid claims are filed. Payments will be made pro rata, meaning the more you spent, the larger your share. Because losartan is a long-term prescription for blood pressure management, people who took Vivimed losartan for months or years could see meaningful payouts.
Do I Need Proof?
The notice says documentation should be submitted if possible, but does not strictly require proof of purchase upfront. Here is what the settlement administrator will do:• You file your claim form and describe your Vivimed losartan purchases.
• The administrator reviews your claim for fraud or mistaken claims.
• If your documentation is insufficient to approve the claim, the administrator may contact you for proof of purchase from your pharmacy.
• You then provide the requested documentation.
To prevent delays, it is best to include whatever proof you have with your initial claim. Acceptable documentation includes pharmacy receipts, prescription bottle labels showing the NDC, insurance explanation of benefits statements, or a pharmacy-printed prescription history. Your pharmacy can print your prescription history for free.
How Do I File a Claim?
Submit your claim online at SartanMedicationSettlement.com, or download a paper claim form from that website and mail the completed form to the Settlement Administrator at the address listed in the official notice. Your claim must be submitted online or postmarked by June 2, 2026.This settlement is part of a broader group of three related settlements involving contaminated blood pressure drugs. If you also purchased Hetero valsartan (sold May – July 2018) or Aurobindo irbesartan (sold January 2016 to present), you can file a claim for those settlements through the same website. See our combined blood pressure drug settlement page for details on all three, or our news alert, $15.26 million blood pressure drug settlement deadline (June 2, 2026), if you are filing on the last day.
When Will Payments Be Sent?
The final approval hearing is scheduled for June 30, 2026 at 10:00 AM at the U.S. District Court for the District of New Jersey, before Judge Renee M. Bumb. If the court grants final approval and no appeals are filed, the settlement administrator will begin distributing payments after the effective date. The exact timing depends on the court's final approval order and how long claims processing takes.Case Information
This settlement is part of In re: Valsartan, Losartan, and Irbesartan Products Liability Litigation, Case No. 1:19-md-02875-RBK-SAK (MDL No. 2875), in the U.S. District Court for the District of New Jersey, before Judge Renee M. Bumb. The defendants are Vivimed Life Sciences Pvt Ltd and Strides Pharma Science Limited, and the settlement also covers losartan repackaged by Heritage Pharmaceuticals Inc. (d/b/a Avet Pharmaceuticals Inc.). Class counsel are Slack Davis Sanger LLP, Honik Law, and Kanner & Whiteley LLC. The class representatives are Jacqueline Harris (consumer) and MSP Recovery Claims Series LLC (third-party payor). The class is defined by the impacted NDCs 23155-644-09 through 23155-646-10. The claim, opt-out, and objection deadlines are all June 2, 2026.Free settlement alerts
Get notified when new class actions open to claims
Join thousands of readers who get the latest class action settlements you may qualify for — delivered straight to your inbox.
Claim Form Website: SartanMedicationSettlement.com
Submit Claim
Official Settlement Notice (PDF)
Sources
• Official Settlement Website — SartanMedicationSettlement.com• Court-authorized Vivimed Settlement Notice, In re: Valsartan, Losartan, and Irbesartan Products Liability Litigation, Case No. 1:19-md-02875-RBK-SAK (D.N.J., filed Dec. 3, 2025)
• OpenClassActions — Combined Valsartan, Losartan, Irbesartan Settlement Overview
• OpenClassActions — Hetero Valsartan Settlement In-Depth Guide ($11.37M)
• OpenClassActions — Aurobindo Irbesartan Settlement ($2M)
For more class actions keep scrolling below.
Settlement Amount
$1,899,000
Case Title
In re: Valsartan, Losartan, and Irbesartan Products Liability Litigation
Case Number
1:19-md-02875-RBK-SAK (MDL No. 2875)
Court
U.S. District Court, District of New Jersey
Final Approval Hearing
June 30, 2026 at 10:00 AM
D.N.J. · Judge Renee M. Bumb
Defendants
Vivimed Life Sciences Pvt Ltd, Strides Pharma Science Limited
Official Website
Sartan Medication Settlement.com
